Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-08-21 Regulatory Filings
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-08-21 English
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri félagsins
Earnings Release Classification · 100% confidence The document is a comprehensive quarterly financial update from Oculis, detailing operational milestones, clinical trial progress, and financial statements (balance sheet and income statement) for the period ending June 30, 2025. While it is presented as a press release, it contains the full financial data and management commentary typical of an interim report. Given the depth of the financial tables and the reporting period, it is classified as an Interim/Quarterly Report. Q2 2025
2025-08-21 Icelandic
Oculis Reports Q2 2025 Financial Results and Provides Company Update
Earnings Release Classification · 100% confidence The document is a press release from Oculis Holding AG announcing their Q2 2025 financial results. It includes key highlights, clinical trial updates, and condensed financial statements (balance sheet and income statement). While it contains financial data, it is a standard quarterly earnings release (ER) rather than a full interim report (IR) or a 10-K, as it is formatted as a news release with contact information and forward-looking statements. Q2 2025
2025-08-21 English
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that Oculis management will participate in an upcoming investor conference. It provides details about the event, the speakers, and where to find the presentation materials. It does not contain the actual presentation slides or a transcript, but rather serves as an announcement of participation and availability of future materials. Under the 'Menu vs Meal' rule, this is an announcement rather than the report itself, and it fits best as a general regulatory filing or announcement.
2025-08-12 English
6-K
Regulatory Filings
2025-08-01 English
Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF
Capital/Financing Update Classification · 100% confidence The document is a press release from Oculis Holding AG announcing an amendment to their credit facility agreement with BlackRock, increasing their borrowing capacity to 100 million CHF. This falls under the category of corporate financing and capital structure updates. It is not a report itself, but an announcement of a financial event, fitting the 'Capital/Financing Update' category.
2025-08-01 Icelandic

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.